The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
Open accessAbstract
PURPOSE: Clinicopathologic features and biochemical recurrence are sensitive, but not specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a genomic expression signature detected in the primary tumor represents true biological potential of aggressive disease and provides improved prediction of early prostate cancer metastasis. METHODS: A nested case-control design was used to select 639 patients from the Mayo Clinic tumor registry who underwent radical prostatectomy between 1987 and 2001. A genomic classifier (GC) was developed by modeling differential RNA expression using 1.4 million feature high-density expression arrays of men enriched for rising PSA after prostatectomy, including 213 who experienced early clinical metastasis after biochemical recurrence. A training set was used to develop a random forest classifier of 22 markers to predict for cases--men with early clinical metastasis after rising PSA. Performance of GC was compared to prognostic factors such as Gleason score and previous gene expression signatures in a withheld validation set. RESULTS: Expression profiles were generated from 545 unique patient samples, with median follow-up of 16.9 years. GC achieved an area under the receiver operating characteristic curve of 0.75 (0.67-0.83) in validation, outperforming clinical variables and gene signatures. GC was the only significant prognostic factor in multivariable analyses. Within Gleason score groups, cases with high GC scores experienced earlier death from prostate cancer and reduced overall survival. The markers in the classifier were found to be associated with a number of key biological processes in prostate cancer metastatic disease progression. CONCLUSION: A genomic classifier was developed and validated in a large patient cohort enriched with prostate cancer metastasis patients and a rising PSA that went on to experience metastatic disease. This early metastasis prediction model based on genomic expression in the primary tumor may be useful for identification of aggressive prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
Classification and Regression by randomForest
Liaw, A. I., & Wiener, M. C. (2007) · Cited by 18,594
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
HMDB 3.0—The Human Metabolome Database in 2013
Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1065 · Cited by 2,845
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
A molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W. J., & Pandolfi, P. P. (2010) · Nature · doi:10.1038/nature09144 · Cited by 2,323
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,234
Tackling the widespread and critical impact of batch effects in high-throughput data
Leek, J. T., Scharpf, R. B., Bravo, H. C., Simcha, D., Langmead, B., Johnson, W. E., Geman, D., Baggerly, K., & Irizarry, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2825 · Cited by 2,196
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Gene map of the extended human MHC
Horton, R., Wilming, L., Rand, V., Lovering, R. C., Bruford, E. A., Khodiyar, V. K., Lush, M. J., Povey, S., Talbot, C. C., Wright, M. W., et al. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1489 · Cited by 1,198
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1914 · Cited by 1,029
CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS
HULL, G. W., RABBANI, F., ABBAS, F., WHEELER, T. M., KATTAN, M. W., & SCARDINO, P. T. (2002) · Journal of Urology · doi:10.1016/s0022-5347(01)69079-7 · Cited by 964
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2329 · Cited by 897
Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. B., & Nelson, W. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11733 · Cited by 838
Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, R., Störkel, S., Willich, N., Semjonow, A., Souchon, R., Stöckle, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9563 · Cited by 825
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1735 · Cited by 673
α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer
Rubin, M. A. (2002) · JAMA · doi:10.1001/jama.287.13.1662 · Cited by 644
Frozen robust multiarray analysis (fRMA)
McCall, M. N., Bolstad, B. M., & Irizarry, R. A. (2010) · Biostatistics · doi:10.1093/biostatistics/kxp059 · Cited by 590
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Gene expression profiling predicts clinical outcome of prostate cancer
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M., & Gerald, W. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20032 · Cited by 479
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Möller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455
A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 348
Elevated expression of caveolin is associated with prostate and breast cancer.
Yang, G., Truong, L. D., Timme, T. L., Ren, C., Wheeler, T. M., Park, S. H., Nasu, Y., Bangma, C. H., Kattan, M. W., Scardino, P. T., et al. (1998) · PubMed · Cited by 331
Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., Inman, B. A., Krambeck, A. E., Mckenney, M. E., Karnes, R. J., Blute, M. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1068 · Cited by 267
Self-citationChung, E. Y., Liu, J., Homma, Y., Zhang, Y., Brendolan, A., Saggese, M., Han, J., Silverstein, R., Selleri, L., & Ma, X. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.014 · Cited by 248
Chen, H., Tu, S.-W., & Hsieh, J.-T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501379200 · Cited by 239
MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines
Viticchiè, G., Lena, A. M., Latina, A., Formosa, A., Gregersen, L. H., Lund, A. H., Bernardini, S., Mauriello, A., Miano, R., Spagnoli, L. G., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15180 · Cited by 209
Nakagawa, T., Kollmeyer, T. M., Morlan, B. W., Anderson, S. K., Bergstralh, E. J., Davis, B. J., Asmann, Y. W., Klee, G. G., Ballman, K. V., & Jenkins, R. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002318 · Cited by 179
Self-citationCensoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Stephenson, A. J., Smith, A., Kattan, M. W., Satagopan, J., Reuter, V. E., Scardino, P. T., & Gerald, W. L. (2005) · Cancer · doi:10.1002/cncr.21157 · Cited by 164
mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer
Penney, K. L., Sinnott, J. A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., Stark, J. R., Fiorentino, M., Perner, S., Finn, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6421 · Cited by 158
for The Trans-Atlantic Prostate Group, Berney, D. M., Gopalan, A., Kudahetti, S. C., Fisher, G., Ambroisine, L., Foster, C. S., Reuter, V., Eastham, J. A., Møller, H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604951 · Cited by 135
Barcellos, L. F., May, S. L., Ramsay, P. P., Quach, H. L., Lane, J. A., Nititham, J., Noble, J. A., Taylor, K. E., Quach, D. L., Chung, S. A., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000696 · Cited by 131
Kristiansen, G., Fritzsche, F., Wassermann, K., Jäger, C., Tölle, A., Lein, M., Stephan, C., Jung, K., Pilarsky, C. P., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604614 · Cited by 130
Olmos, D., Brewer, D. S., Clark, J., Danila, D. C., Parker, C. C., Attard, G., Fleisher, M., Reid, A. H. M., Castro, E., Sandhu, S. K., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70372-8 · Cited by 122
Identification of markers of prostate cancer progression using candidate gene expression
Larkin, S. E. T., Holmes, S., Cree, I. A., Walker, T., Basketter, V., Bickers, B., Harris, S., Garbis, S. D., Townsend, P. A., & Hastie, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.490 · Cited by 119
Contemporary Grading for Prostate Cancer: Implications for Patient Care
Brimo, F., Montironi, R., Egevad, L., Erbersdobler, A., Lin, D. W., Nelson, J. B., Rubin, M. A., van der Kwast, T., Amin, M. B., & Epstein, J. I. (2012) · European Urology · doi:10.1016/j.eururo.2012.10.015 · Cited by 116
Veeramani, S., Yuan, T., Chen, S.-J., Lin, F., Petersen, J. E., Shaheduzzaman, S., Srivastava, S. K., MacDonald, R. G., & Lin, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00950 · Cited by 112
Ross, R. W., Galsky, M. D., Scher, H. I., Magidson, J., Wassmann, K., Lee, G. M., Katz, L., Subudhi, S. K., Anand, A., Fleisher, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70263-2 · Cited by 110
Expression signatures that correlated with Gleason score and relapse in prostate cancer
Bibikova, M. V., Chudin, E., Arsanjani, A. H., Zhou, L., Wickham‐Garcia, E., Modder, J. K., Kostelec, M., Barker, D. L. A., Downs, T. M., Fan, J., et al. (2007) · Genomics · doi:10.1016/j.ygeno.2007.02.005 · Cited by 110
Singh, A. P., Bafna, S., Chaudhary, K. R., Venkatraman, G., Smith, L. M., Eudy, J. D., Johansson, S. L., Lin, M., & Batra, S. K. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.09.018 · Cited by 110
Defining Aggressive Prostate Cancer Using a 12-Gene Model
Bismar, T. A., Demichelis, F., Riva, A., Kim, R., Varambally, S., He, L., Kutok, J. L., Aster, J. C., Tang, J., Kuefer, R., et al. (2006) · Neoplasia · doi:10.1593/neo.05664 · Cited by 107
Berg, C. V. D., Guan, X., Hoff, D. V., et al. (1995) · PubMed · Cited by 103
Exon array data analysis using Affymetrix power tools and R statistical software
Lockstone, H. E. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbq086 · Cited by 100
Cheville, J. C., Karnes, R. J., Therneau, T. M., Kosari, F., Munz, J.-M., Tillmans, L. S., Basal, E., Rangel, L. J., Bergstralh, E. J., Kovtun, I. V., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6752 · Cited by 84
Self-citationNGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate
Bera, T. K., Das, S., Maeda, H., Beers, R., Wolfgang, C. D., Vasantha Kumar, M. V., Hahn, Y., Lee, B., & Pastan, I. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308746101 · Cited by 78
A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer
Agell, L., Hernandez, S. F., Nonell, L., Lorenzo, M., Puigdecanet, E., de Muga, S., Juanpere-Rodero, N., Bermudo, R., Fernández, P. L., Lorente, J. A., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.08.005 · Cited by 64
Chen, Q., Watson, J. T., Marengo, S. R., Decker, K., Coleman, I. M., Nelson, P. S., & Sikes, R. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.027 · Cited by 61
Prognostic Factors for Failure after Prostatectomy
Swanson, G. P., & Basler, J. W. (2011) · Journal of Cancer · doi:10.7150/jca.2.1 · Cited by 57
Chromosome 17q12 Variants Contribute to Risk of Early-Onset Prostate Cancer
Levin, A. M., Machiela, M. J., Zuhlke, K. A., Ray, A. M., Cooney, K. A., & Douglas, J. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0348 · Cited by 48
Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?
Patel, A. R., & Stephenson, A. J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.80 · Cited by 34
Genomic “Dark Matter” in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers
Vergara, I. A., Erho, N., Triche, T. J., Ghadessi, M., Crisan, A., Sierocinski, T., Black, P. C., Buerki, C., & Davicioni, E. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00023 · Cited by 24
Self-citationTalantov, D., Jatkoe, T. A., Böhm, M., Zhang, Y., Ferguson, A. M., Stricker, P. D., Kattan, M. W., Sutherland, R. L., Kench, J. G., Wang, Y., et al. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.05.084 · Cited by 14
Cited by
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Self-citationGenetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Metadata
- Authors
- Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., Zimmermann, B., Sierocinski, T., Ballman, K. V., Triche, T. J., Black, P. C., Karnes, R. J., Klee, G., Davicioni, E., & Jenkins, R. B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-24
- Volume
- 8
- Issue
- 6
- Pages
- e66855
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1998343146
- Cited by
- 644
- References
- 67
- FWCI
- 31.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.